STOCK TITAN

TELA Bio Inc - TELA STOCK NEWS

Welcome to our dedicated news page for TELA Bio (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on TELA Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TELA Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TELA Bio's position in the market.

Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA) took part in Connecting the Dots, a series of branded films presented by MedTech Europe, including a film produced by BBC StoryWorks Commercial Productions. The series will feature a mini-documentary highlighting the use of OviTex® Reinforced Tissue Matrix in hernia repair, addressing the need for newer alternatives in hernia surgery. Surgeons perform an estimated 20 million hernia repair procedures annually, and the series aims to showcase the role of medical technologies in improving global healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.68%
Tags
none
-
Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA) to participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA's management will present at the conference on November 30th, 2023, focusing on innovative soft-tissue reconstruction solutions. Interested parties can access the webcast at ir.telabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
-
Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA) announced the approval of inducement grants of restricted stock units to thirty-one newly-hired employees as part of their employment compensation. The grants, totaling 40,700 shares, were made to optimize clinical outcomes and prioritize patient anatomy preservation and restoration. The restricted stock units will vest in equal annual installments over four years, subject to continued service with TELA Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
TELA Bio, Inc. (TELA) reports 35% revenue growth in Q3 2023, reaching $15.1 million. OviTex and OviTex PRS products showed significant growth, with updated full year revenue guidance of $57.0 million to $60.0 million. The company remains committed to executing solid, steady growth quarter-after-quarter, positioning well for future success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.37%
Tags
-
Rhea-AI Summary
TELA Bio, Inc. will report third quarter 2023 financial results on November 9, 2023. The company focuses on providing soft-tissue reconstruction solutions. A conference call and webcast will be held to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
-
Rhea-AI Summary
TELA Bio, Inc. to present at Gilmartin Group Emerging Growth Company Showcase on September 21st, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences acquisition
Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA) has announced the launch of their OviTex PRS Long-Term Resorbable product, expanding their reconstruction options for surgeons and patients. The product is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. With 6,800+ implantations at over 400 healthcare facilities, OviTex PRS is the only biologic reinforced with interwoven polymer sutures designed specifically for plastic and reconstructive surgery. The OviTex PRS portfolio provides multiple resorption, stretch, and shape offerings to meet the unique needs of each patient.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
-
Rhea-AI Summary
TELA Bio approves inducement grants of restricted stock units to newly-hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
TELA Bio Inc

Nasdaq:TELA

TELA Rankings

TELA Stock Data

121.28M
15.79M
2.54%
86.87%
3.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Malvern

About TELA

tela bio, inc., a surgical reconstruction company, was created out of the desire to do things differently. combining the drive and innovation of a start-up with a seasoned medical technology team, the company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. based in malvern, pennsylvania, this science-driven company is collaborating with leading surgeons to reinvigorate the soft tissue reconstruction market and bring cost-effective solutions to hospitals, surgeons and patients. please see our social media community guidelines at http://bit.ly/1uvcx0l